Marshall Wace
SGMO

Marshall Wace’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Marshall Wace’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76K Buy
+303,862
New +$121K ﹤0.01% 2931
2025
Q2 		– Sell
-651,906
Closed -$430K – 3114
2025
Q1 		$430K Buy
651,906
+314,776
+93% +$333K ﹤0.01% 2136
2024
Q4 		$344K Sell
337,130
-2,016,626
-86% -$3.69M ﹤0.01% 2192
2024
Q3 		$2.05M Buy
2,353,756
+1,777,537
+308% +$1.3M ﹤0.01% 1355
2024
Q2 		$207K Buy
576,219
+207,476
+56% +$112K ﹤0.01% 2288
2024
Q1 		$247K Buy
+368,743
New +$267K ﹤0.01% 2172
2020
Q4 		– Sell
-11,127
Closed -$105K – 2141
2020
Q3 		$105K Buy
+11,127
New +$120K ﹤0.01% 1515
2020
Q2 		– Sell
-1,363,039
Closed -$8.68M – 1898
2020
Q1 		$8.68M Buy
1,363,039
+1,033,713
+314% +$7.67M 0.09% 240
2019
Q4 		$2.76M Buy
329,326
+296,968
+918% +$2.73M 0.02% 718
2019
Q3 		$293K Buy
+32,358
New +$363K ﹤0.01% 1210
2019
Q1 		– Sell
-712,657
Closed -$8.18M – 2030
2018
Q4 		$8.18M Buy
712,657
+699,089
+5,152% +$8.68M 0.08% 302
2018
Q3 		$230K Buy
+13,568
New +$206K ﹤0.01% 1048
2017
Q3 		– Sell
-56,314
Closed -$507K – 409
2017
Q2 		$507K Buy
+56,314
New +$361K 0.02% 240

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Marshall Wace's SGMO Position: Q1 2026 in Review

Marshall Wace opened a new position in SANGAMO THERAPEUTICS INC (SGMO) in Q1 2026: 303,862 shares worth $76K. The stake represents ﹤0.01% of the portfolio and ranks #2931 among its holdings. This is a return to the name: Marshall Wace previously reported a position in SGMO as recently as Q1 2025.

Marshall Wace first reported a position in SGMO in Q2 2017 and has held it in 13 quarters since. The position peaked at $8.68M in Q1 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Marshall Wace held 303,862 shares of SANGAMO THERAPEUTICS INC worth $76K as of Q1 2026.
  • SANGAMO THERAPEUTICS INC was a new Marshall Wace position in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2931 holding.
  • Marshall Wace first reported a position in SANGAMO THERAPEUTICS INC in Q2 2017 and has held it in 13 quarters since.
  • Marshall Wace's SANGAMO THERAPEUTICS INC position peaked at $8.68M in Q1 2020.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.